Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)

About Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INFI
  • CUSIP: 45665G30
  • Web:
  • Market Cap: $70.62 million
  • Outstanding Shares: 50,443,000
Average Prices:
  • 50 Day Moving Avg: $1.66
  • 200 Day Moving Avg: $2.12
  • 52 Week Range: $0.84 - $3.84
  • Trailing P/E Ratio: 700.00
  • Foreward P/E Ratio: -0.99
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $9.47 million
  • Price / Sales: 7.46
  • Book Value: $1.46 per share
  • Price / Book: 0.96
  • EBIDTA: ($88,200,000.00)
  • Return on Equity: -77.26%
  • Return on Assets: -51.26%
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 7.60%
  • Quick Ratio: 7.60%
  • Average Volume: 499,279 shs.
  • Beta: 2.63
  • Short Ratio: 2.61
Frequently Asked Questions for Infinity Pharmaceuticals (NASDAQ:INFI)

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its earnings results on Tuesday, May, 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $19.60 million. The firm's revenue was down 99.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.82) EPS. View Infinity Pharmaceuticals' Earnings History.

Where is Infinity Pharmaceuticals' stock going? Where will Infinity Pharmaceuticals' stock price be in 2017?

4 analysts have issued 1-year price targets for Infinity Pharmaceuticals' stock. Their forecasts range from $1.00 to $1.00. On average, they expect Infinity Pharmaceuticals' share price to reach $1.00 in the next year. View Analyst Ratings for Infinity Pharmaceuticals.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a decrease in short interest in June. As of June 30th, there was short interest totalling 1,512,502 shares, a decrease of 55.8% from the June 15th total of 3,420,737 shares. Based on an average trading volume of 993,299 shares, the short-interest ratio is presently 1.5 days. Currently, 3.1% of the shares of the company are sold short.

Who are some of Infinity Pharmaceuticals' key competitors?

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:

  • Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer
  • Lawrence E. Bloch M.D. J.D., President, Principal Financial Officer, Principal Accounting Officer
  • William C. Bertrand Jr., J.D., Executive Vice President, General Counsel
  • Melissa Hackel, Vice President - Finance
  • Joseph Pearlberg M.D. Ph.D., Vice President - Clinical Development
  • Norman C. Selby, Lead Outside Independent Director
  • Jose Baselga M.D., Ph.D., Independent Director
  • Jeffrey Berkowitz J.D., Independent Director
  • Anthony B. Evnin Ph.D., Independent Director
  • Michael G. Kauffman M.D., Ph.D., Independent Director

How do I buy Infinity Pharmaceuticals stock?

Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $1.40.

MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Infinity Pharmaceuticals (NASDAQ:INFI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.00 (28.57% downside)

Analysts' Ratings History for Infinity Pharmaceuticals (NASDAQ:INFI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/11/2016Morgan StanleyReiterated RatingHold$1.00N/AView Rating Details
8/10/2016FBR & CoReiterated RatingHoldN/AView Rating Details
8/9/2016WedbushReiterated RatingNeutral$1.25 -> $1.00N/AView Rating Details
6/15/2016Jefferies Group LLCDowngradeBuy -> HoldN/AView Rating Details
6/15/2016William BlairDowngradeOutperform -> Market Perform$20.00 -> $2.00N/AView Rating Details
6/15/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
6/14/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$12.00 -> $2.00N/AView Rating Details
6/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Earnings by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Earnings History by Quarter for Infinity Pharmaceuticals (NASDAQ INFI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.22)($0.21)$19.60 million$0.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.57)($0.46)$2.33 millionViewN/AView Earnings Details
11/9/2016Q316($0.84)($0.39)$6.23 millionViewListenView Earnings Details
8/9/2016Q216($0.89)$1.05$13.91 million$9.47 millionViewListenView Earnings Details
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details
11/5/2015Q315($0.76)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details
5/6/2015Q115($1.69)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details
2/24/2015Q414($0.99)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details
11/6/2014Q314($0.87)$2.03$141.40 million$160.60 millionViewListenView Earnings Details
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details
5/6/2014Q1($0.80)($0.87)ViewListenView Earnings Details
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)
2017 EPS Consensus Estimate: ($0.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.23)($0.13)($0.18)
Q2 20172($0.21)($0.12)($0.17)
Q3 20172($0.21)($0.13)($0.17)
Q4 20172($0.21)($0.13)($0.17)
(Data provided by Zacks Investment Research)


Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Ownership Percentage: 6.81%
Institutional Ownership Percentage: 76.49%
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/17/2017Michael C VenutiDirectorSell6,250$3.48$21,750.00View SEC Filing  
1/3/2017Value Fund L P BiotechnologyMajor ShareholderBuy4,379$1.34$5,867.86View SEC Filing  
12/30/2016Value Fund L P BiotechnologyMajor ShareholderBuy742,401$1.34$994,817.34View SEC Filing  
12/20/2016Value Fund L P BiotechnologyMajor ShareholderBuy654,921$1.31$857,946.51View SEC Filing  
12/13/2016Sujay KangoInsiderSell75,000$1.28$96,000.00View SEC Filing  
12/12/2016Sujay KangoInsiderSell25,009$1.30$32,511.70View SEC Filing  
12/2/2016Value Fund L P BiotechnologyMajor ShareholderBuy201,394$1.19$239,658.86View SEC Filing  
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00View SEC Filing  
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Infinity Pharmaceuticals (NASDAQ:INFI)
Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
DateHeadline logoFinancial Survey: Celator Pharmaceuticals (CPXX) versus Infinity Pharmaceuticals (INFI) - July 21 at 6:06 PM logoInfinity Announces the Date of Its Second Quarter 2017 Financial Results Conference Call and Webcast - July 21 at 3:58 PM logoInfinity Pharmaceuticals, Inc. (INFI) Short Interest Update - July 16 at 7:23 AM logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Rating Increased to Hold at ValuEngine - July 8 at 11:26 PM logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Given Average Rating of "Hold" by Brokerages - July 7 at 12:44 PM logoCompany Spotlight: Verastem - July 7 at 6:29 AM logoZacks: Brokerages Expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to Post -$0.22 Earnings Per Share - July 6 at 10:30 AM logoValuEngine Upgrades Infinity Pharmaceuticals, Inc. (INFI) to Sell - June 15 at 8:50 PM logoInfinity to Participate in Three Upcoming Conferences - PR Newswire (press release) - June 15 at 6:13 AM logoInfinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound? - Nasdaq - June 14 at 11:23 AM logoInfinity to Participate in Three Upcoming Conferences - June 14 at 11:23 AM logoInfinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound? - June 13 at 10:55 AM logoInfinity Pharmaceuticals Inc. (INFI) Receives Consensus Recommendation of "Hold" from Analysts - June 12 at 12:34 PM logoInfinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.22 Per Share - June 12 at 10:24 AM logoInfinity Pharmaceuticals Inc. (INFI) Stock Rating Lowered by ValuEngine - June 4 at 11:14 AM logoInfinity Pharmaceuticals Inc. (INFI) Given Average Rating of "Hold" by Brokerages - May 16 at 2:34 PM logoInfinity Pharmaceuticals Inc. (INFI) Downgraded by Zacks Investment Research - May 16 at 1:34 PM logoInfinity Pharmaceuticals Inc. (INFI) Short Interest Update - May 13 at 7:20 AM logoQ2 2017 Earnings Forecast for Infinity Pharmaceuticals Inc. (INFI) Issued By William Blair - May 12 at 9:37 AM logoVerastem Reports First Quarter 2017 Financial Results - May 10 at 6:21 PM logoEdited Transcript of INFI earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 6:21 PM logoInfinity Provides Company Update and Reports First Quarter 2017 ... - PR Newswire (press release) - May 10 at 1:18 PM logoInfinity (INFI) Reports Narrower-than-Expected Loss in Q1 - May 10 at 1:18 PM logoInfinity Pharmaceuticals Inc. (INFI) Posts Earnings Results, Beats Expectations By $0.08 EPS - May 9 at 9:22 PM logoInfinity reports 1Q loss - May 9 at 5:44 PM logoBRIEF-Infinity reports Q1 loss per share $0.21 - May 9 at 5:43 PM logoInfinity Provides Company Update and Reports First Quarter 2017 Financial Results - May 9 at 5:43 PM logoInvestor Network: Infinity Pharmaceuticals, Inc. to Host Earnings Call - May 9 at 12:23 PM logoHorizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed - May 9 at 12:23 PM logoCatalent (CTLT) Shows Strength: Stock Adds 9.8% in Session - May 8 at 7:29 AM logoVerastem Boosts Oncologic Drug Portfolio, Fuels Stock Price - May 7 at 6:18 PM logoRegeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates - May 4 at 6:05 PM logoInfinity Pharmaceuticals (INFI) Earning Favorable Media Coverage, Study Finds - May 3 at 10:36 AM logoInfinity Pharmaceuticals (INFI) Earning Somewhat Favorable Media Coverage, Report Shows - April 27 at 11:50 PM logoInfinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast - April 26 at 7:26 PM logoSomewhat Positive News Coverage Very Likely to Affect Infinity Pharmaceuticals (INFI) Share Price - April 21 at 8:09 PM logoAbbVie (ABBV) Presents Positive Data on HCV Combination Drug - April 21 at 10:39 AM logoToday's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals - Yahoo Finance - April 20 at 6:00 PM logoInfinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19% - Yahoo Finance - April 20 at 6:00 PM logoETFs with exposure to Infinity Pharmaceuticals, Inc. : April 19, 2017 - April 19 at 5:48 PM logoWhy Is Infinity (INFI) Down 37.4% Since the Last Earnings Report? - April 19 at 11:25 AM logoUltragenyx's Hypophosphatemia Drug Succeeds in Phase III - April 19 at 11:25 AM logoInfinity Pharmaceuticals (INFI) Earns Coverage Optimism Score of 0.08 - April 18 at 2:54 PM logoGainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY... - April 18 at 11:03 AM logoToday's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals - April 18 at 11:03 AM logoInfinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19% - April 18 at 11:03 AM logoBio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher - April 17 at 10:50 AM logoNew Strong Buy Stocks for April 10th - April 10 at 11:00 AM logoCardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session - April 10 at 11:00 AM logoInfinity Pharmaceuticals Focuses on Lead Candidate IPI-549 - April 10 at 11:00 AM



Infinity Pharmaceuticals (INFI) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff